Dr. Jonathan Trent on FDA Approval of Trabectedin for Soft Tissue Sarcomas

14 意见
administrator
administrator
07/18/23

Jonathan C. Trent, MD, professor of Medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.

  • 类别

显示更多

0 注释 排序方式

没有找到评论

脸书评论

下一个